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Transgenic mice expressing exon 1 of the human Huntington’s
disease (HD) gene carrying a 141–157 CAG repeat (line R6/2)
develop a progressive neurological phenotype with motor
symptoms resembling those seen in HD. We have character-
ized the motor deficits in R6/2 mice using a battery of behav-
ioral tests selected to measure motor aspects of swimming,
fore- and hindlimb coordination, balance, and sensorimotor
gating [swimming tank, rotarod, raised beam, fore- and hind-
paw footprinting, and acoustic startle/prepulse inhibition (PPI)].
Behavioral testing was performed on female hemizygotic R6/2
transgenic mice (n 5 9) and female wild-type littermates (n 5
22) between 5 and 14 weeks of age. Transgenic mice did not
show an overt behavioral phenotype until around 8 weeks of
age. However, as early as 5–6 weeks of age they had significant
difficulty swimming, traversing the narrowest square (5 mm)
raised beam, and maintaining balance on the rotarod at rotation
speeds of 33–44 rpm. Furthermore, they showed significant
impairment in prepulse inhibition (an impairment also seen in
patients with HD). Between 8 and 15 weeks, R6/2 transgenic
mice showed a progressive deterioration in performance on all
of the motor tests. Thus R6/2 mice show measurable deficits in
motor behavior that begin subtly and increase progressively
until death. Our data support the use of R6/2 mice as a model
of HD and indicate that they may be useful for evaluating
therapeutic strategies for HD, particularly those aimed at re-
ducing the severity of motor symptoms or slowing the course of
the disease.
Key words: transgenic mice; Huntington’s disease; CAG re-
peat; motor behavior; prepulse inhibition; sensorimotor gating;
polyglutamine repeat diseases
Huntington’s disease (HD) is a progressive, genetic neurodegen-
erative disorder characterized by movement abnormalities, cog-
nitive impairments, and an emotional disturbance (Harper,
1996). The predominant movement abnormality is chorea, al-
though other motor abnormalities including dyskinesia, dystonia,
rigidity, and tremor are also seen, the latter particularly in
juvenile-onset HD.
An expanded unstable CAG trinucleotide repeat within the
coding region of the HD gene has been identified as the genetic
mutation responsible for the disease (The Huntington’s Disease
Collaborative Group, 1993). It now appears that HD belongs to a
family of neurodegenerative disorders associated with an expan-
sion of CAG repeats in the causative gene. To date, seven addi-
tional CAG “triplet repeat” diseases have been identified, includ-
ing spinal and bulbar muscular atrophy, spinocerebellar ataxia
types 1, 2, 3, 6, and 7, and dentatorubral-pallidoluysian atrophy
(for references, see Paulson and Fischbeck, 1997). The causative
genes in each of these disorders are different and unrelated in
function, although the expansion of the CAG repeats and the
progressive neurological nature of these disorders suggests that
they may share a common mechanism of pathogenesis (Mac-
Donald and Gusella, 1996; Burright et al., 1997).
Over the past 20 years, many attempts have been made to
generate animal models of HD. Of particular importance have
been the excitotoxic and 3-nitropropionic acid (3-NP) models that
replicate many of the histological features of HD in both rodents
and primates (Beal et al., 1986, 1993; Brouillet et al., 1995). 3-NP
models in particular reportedly model some of the motor symp-
toms of HD, including abnormalities in gait and impairments in
sensorimotor gating (Borlongan et al., 1995; Brouillet et al., 1995;
Kodsi and Swerdlow, 1997). However, because both models are
neurochemically induced, the associated changes in behavior are
not truly progressive. Thus they are limited in their usefulness for
testing treatments aimed at preventing or slowing the motor
dysfunction in HD. An animal model that exhibits a progressive
neurological phenotype is essential before such studies can be
usefully conducted.
A transgenic mouse model for HD (R6/2) that appears to have
a progressive phenotype has been developed recently (Mangia-
rini et al., 1996). R6/2 mice, whose transgene contains the first
exon of the human HD gene carrying 141–157 CAG repeats,
display a number of the key neuropathological features of HD
(Davies et al., 1997; Cha et al., 1998). Critically, preliminary
investigations showed that R6/2 transgenic mice develop several
of the motoric characteristics of HD (Mangiarini et al., 1996),
including a progressive hypoactivity similar to that seen in pa-
tients with HD (Carter et al., 1998; Dunnett et al., 1998). How-
ever, so far the behavioral phenotype of this mouse has not been
analyzed in sufficient detail to determine its usefulness as a
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progressive model of HD. Therefore, in this study we have
characterized the progressive motor deficits displayed by R6/2
transgenic mice. These data will provide a baseline against which
to assess (1) the relevance of this mouse model to HD and (2) its
potential usefulness for testing therapies aimed at treating this
devastating disease.
MATERIALS AND METHODS
Animals (R6/2 transgenic mice). The R6/2 line of transgenic mice was
generated as described previously (Mangiarini et al., 1996). A colony of
R6/2 transgenic mice was established in the Department of Pharmacol-
ogy, University of Cambridge, and the line was maintained by backcross-
ing to CBA 3 C57BL/6 F1 animals. Genotyping was confirmed by PCR
based on a modification of the method of Mangiarini et al. (1996). The
present study used 9 female hemizygotic transgenic mice and 22 female
wild-type littermate control mice from six litters of the thirteenth gen-
eration, all born within 5 d of each other. Females were used because
transgenic males were used for breeding and were not available for
behavioral testing. The age of onset of overt symptoms in the R6/2 line
is ;2 months, with the severity of symptoms progressing rapidly over the
following few weeks, as reported previously (Mangiarini et al., 1996).
Here, behavioral testing began at 5–6 weeks of age, when transgenic mice
were overtly phenotypically indistinguishable from their normal litter-
mates. Tests were conducted regularly (see below) over a 10 week period
to follow the progression of motor symptoms. One transgenic mouse died
during the final week of the study; data from this mouse were included in
the analysis.
Mice were housed together in numerical birth order in groups of mixed
genotype, and data were recorded for analysis by mouse number. Until
the appearance of the hindlimb grooming behavior, transgenic mice
could not be distinguished from normal mice in their home cage. There-
fore, until the grooming behavior appeared (between 8–9 weeks of age),
the experimenters were blind to the genotype of the mice. Although data
collected after the onset of an overt phenotype was not collected blind,
it should be noted that the home cage observations for overt phenotype
were performed and recorded separately from the behavioral tests.
Because the abnormal grooming in its early stage is difficult to distin-
guish from normal grooming behaviors, this meant that until the abnor-
mal grooming movements occurred regularly, the experimenters did not
necessarily know the genotype of a particular mouse. Once the grooming
behavior and other phenotypic changes became pronounced (usually
between 10 and 14 weeks), it was impossible to conduct the experiments
blind.
Body weight. Body weight was measured twice per week.
Motor tests. Mice were trained on a battery of motor and cognitive
tests. Five motor tests of swimming, fore- and hindlimb coordination,
balance, and sensorimotor gating are reported here. After the establish-
ment of stable baselines, animals were retested at weekly intervals, with
the exception of the acoustic startle test, in which animals were retested
every 2 weeks. The mean age of mice midweek of each testing session was
used for analysis and presentation purposes.
Swimming tank. To monitor swimming movements, mice were trained
to swim from one end of a water-filled glass tank to a visible escape
platform at the opposite end (Perry et al., 1995). The glass tank was 100
cm long and 6 cm wide and was filled to a depth of 20 cm with water at
a temperature of 23°C. The visible escape platform was made from black
perspex (6 cm square and 20.5 cm high), with the top surface 0.5 cm
above the water level. A vertical black line on the side of the glass marked
a horizontal distance 60 cm from the platform; this served as the start
line for recording swimming performance. During the training period
each mouse was placed in the water at one end of the tank, and within a
couple of trials learned to swim straight to the visible escape platform at
the opposite end. After training, mice were given two trials per day for
3 consecutive days, by which time they reached stable baseline perfor-
mance levels. Mice were then given two consecutive trials on a weekly
basis. Mice were videotaped from both sides, and the number of forelimb
kicks, the number of hindlimb kicks, and the latency to swim the 60 cm
distance were recorded. Analysis was based on the mean scores of the
two trials for each measure.
Beam walking. Motor coordination and balance of mice were assessed
by measuring the ability of the mice to traverse a graded series of narrow
beams to reach an enclosed safety platform (Perry et al., 1995). The
beams consisted of long strips of wood (1 m) with a 28-, 12-, or 5-mm-
square cross-section or a 28, 17, or 11 mm round diameter. The beams
were placed horizontally, 50 cm above the bench surface, with one end
mounted on a narrow support and the other end attached to an enclosed
box (20 cm square) into which the mouse could escape. Two anglepoise
lights (60 W) were positioned above and to one side of the start of the
beam. During training, mice were placed at the start of the 12-mm-
square beam and trained over 3 d (4 trials per day) to traverse the beam
to the enclosed box. Once the mice were trained (traversed the 12-mm-
square beam in , 20 sec) they received two consecutive trials on each of
the square beams and each of the round beams, in each case progressing
from the widest to the narrowest beam. Mice were allowed up to 60 sec
to traverse each beam. The latency to traverse each beam and the number
of times the hind feet slipped off each beam were recorded for each trial.
Analysis of each measure was based on the mean scores of the two trials
for each beam.
Rotarod. The rotarod apparatus (Accelerating Model, Ugo Basile,
Biological Research Apparatus, Varese, Italy) was used to measure fore-
and hindlimb motor coordination and balance. During the training
period, each mouse was placed on the rotarod at a constant speed (24
rpm) for a maximum of 60 sec, and the latency to fall off the rotarod
within this time period was recorded. Mice received four trials per day
for 3 consecutive days, by which time a steady baseline level of perfor-
mance was attained. Mice then received two trials at 10 increasing speed
levels, ranging from 5 to 44 rpm. The mean latency to fall off the rotarod
(for the two trials at each speed level) was recorded and used in
subsequent analysis.
Footprint test. The footprint test was used to compare the gait of R6/2
transgenic mice with that of wild-type control mice. To obtain footprints,
the hind- and forefeet of the mice were coated with purple and orange
nontoxic paints, respectively. The animals were then allowed to walk
along a 50-cm-long, 10-cm-wide runway (with 10-cm-high walls) into an
enclosed box. All mice had three training runs and were then given one
run per week. A fresh sheet of white paper was placed on the floor of the
runway for each run. The footprint patterns were analyzed for four step
parameters (all measured in centimeters). (1) Stride length was mea-
sured as the average distance of forward movement between each stride.
(2) Hind-base width and (3) front-base width were measured as the
average distance between left and right hind footprints and left and right
front footprints, respectively. These values were determined by measur-
ing the perpendicular distance of a given step to a line connecting its
opposite preceding and proceeding steps. (4) Distance from left or right
front footprint /hind footprint overlap was used to measure uniformity of
step alternation. When the center of the hind footprint fell on top of the
center of the preceding front footprint, a value of zero was recorded.
When the footprints did not overlap, the distance between the center of
the footprints was recorded. For each step parameter, three values were
measured from each run, excluding footprints made at the beginning and
end of the run where the animal was initiating and finishing movement,
respectively. The mean value of each set of three values was used in
subsequent analysis.
Acoustic startle/prepulse inhibition (PPI). Acoustic startle and PPI re-
sponses were measured in a startle chamber (San Diego Instruments)
adapted for mice. The chosen paradigm was adapted from Swerdlow et
al. (1995) and assessed startle amplitude and PPI using acoustic stimuli of
120 and 105 dB, a single prepulse interval (100 msec), and four different
prepulse intensities [2, 4, 8, and 16 dB above background noise (white
noise, 65 dB)]. A mouse was placed in the startle chamber and initially
received a 5 min acclimatization period with background noise alone.
The mouse was then presented with 72 startle trials, each trial consisting
of one of three conditions: (1) a 30 msec 120 dB noise burst presented
alone (S); (2) a 30 msec 120 dB noise burst preceded 100 msec by
prepulses (30 msec noise bursts) that were 2, 4, 8, or 16 dB above
background noise (PP2, PP4, PP8, or PP16, respectively); or (3) no
stimulus (NS; background noise alone), which was used to measure
baseline movement in the chamber. These six trial types (S, PP2, PP4,
PP8, PP16, NS) were each repeated six times in a pseudorandom order
(36 trials), such that each trial type was presented once within a block of
six trials. This block of 36 trials was then repeated using an acoustic
stimuli of 105 dB. Analysis was based on the mean of the six trials for
each trial type.
Statistical analysis. Behavioral data were subjected to two-, three- or
four-way ANOVA (SAS-RA software package) with one between-
subject factor (genotype; transgenic or wild type) and with repeated
measures on one or more factors depending on the test used (e.g., age,
different beams, different rotarod speeds, etc.). Sidak’s test was used for
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multiple independent post hoc pair-wise comparisons between transgenic
and wild-type mice at each relevant age and test level (Rohlf and Sokal,
1995). A critical value for significance of p , 0.05 was used throughout
the study.
RESULTS
Genotyping
In all cases, mice genotyped as transgenic were those that exhib-
ited a progressive deficit in the motor tests (see below).
Spontaneous appearance of motor deficits in R6/2
transgenic mice
At 5 weeks of age the home cage behavior of R6/2 transgenic mice
was indistinguishable from that of normal littermate control mice.
Overt signs of neurological abnormality were first evident by 8
weeks (58 6 0.5 d) of age, similar to that reported previously
(Mangiarini et al., 1996). The initial abnormal neurological signs
included stereotypical hindlimb-grooming movements, dyskinesia
of the hindlimbs when mice were suspended by the tail, and an
irregular gait. The frequency and severity of these abnormalities
worsened slowly over the following few weeks until by 12–13
weeks of age the animals showed clear signs of irregular gait,
resting tremor, stereotypical grooming, abrupt and irregularly
timed shuddering movements, occasional epileptic seizures, and
body weight loss (see below).
R6/2 transgenic and control mice gained weight at a similar rate
until 10 weeks of age (Fig. 1). The body weight of R6/2 transgenic
mice stabilized at 10 weeks and then showed a gradual decline,
whereas their wild-type littermates continued to grow throughout
the study (genotype 3 age, F22,638 5 47.80, p , 0.0001). A
significant decrease in total body weight in R6/2 transgenic mice
was evident by 13 weeks of age.
Measurement of progression of motor deficits in R6/2
transgenic mice
To assess in more detail the neurological consequences of the
expression of the R6/2 transgene, R6/2 transgenic and wild-type
littermate control mice were subjected to five tests of motor
behavior.
Swimming tank
R6/2 transgenic mice displayed abnormalities in their swimming
movements from the onset of testing, and these became more
marked over subsequent weeks. When placed in the water, R6/2
transgenic mice often floated temporarily, adopted a twisted
posture, and kicked in a splayed and uncoordinated manner with
both hind- and forelimbs. In contrast, control mice swam with
vigor immediately after being placed in the water, using mainly
their hindlimbs to propel along. Although control mice main-
tained a constant swimming latency throughout the study, R6/2
transgenic mice swam significantly more slowly at 5–6 weeks of
age ( p , 0.0001) and swam even more slowly with an increase in
age (genotype 3 age: F8,232 5 13.48, p , 0.0001) (Fig. 2A). At
5–6 weeks of age, R6/2 transgenic mice also exhibited a signifi-
cantly greater number of hind- and forelimb kicks to swim the 60
cm distance, compared with controls [hindlimb: p , 0.01 (Fig.
2B); forelimb: p , 0.05 (Fig. 2C)].
The frequency of hindlimb kicking increased significantly with
the age of the R6/2 transgenic mice, in contrast with the control
group, which sustained a consistent number of hindlimb kicks
over the 10 week period (genotype 3 age: F18,232 5 2.24, p ,
0.05). Although the number of forelimb kicks of R6/2 transgenic
mice was invariably significantly greater than that of their wild-
type littermates across sessions, no significant genotype 3 age
interaction was observed (F8,232 5 2.02, p 5 0.078), because both
groups increased the frequency of forelimb kicking across ses-
sions. The three-way interaction (genotype 3 limb 3 age: F8,464
5 1.34, p 5 0.25) failed to reach significance, suggesting that the
ratio of forelimb to hindlimb kicks was comparable for R6/2
transgenic and control mice (Fig. 2B,C). Swimming impairments,
evident at 5–6 weeks of age, occurred at a time when the R6/2
transgenic animals were otherwise indistinguishable from their
normal littermate controls.
Beam walking
Beam walking was used to compare the fine motor coordination
and balance capabilities of R6/2 transgenic and control animals.
Different levels of task difficulty were achieved by varying the
shape and cross-section of the beams (Fig. 3). At the earliest age
tested, 5–6 weeks, the control and R6/2 transgenic mice walked
along all the beam types with ease, although the R6/2 transgenic
mice were significantly slower in traversing the narrowest square
beam ( p , 0.0001) (Fig. 3C). However, by 8–9 weeks of age
(when home cage phenotypic abnormalities first become appar-
ent), R6/2 transgenic mice showed significant difficulty in travers-
ing all but the widest round beam, as measured by their increased
latency to traverse each beam, compared with control mice. By
13–14 weeks of age, R6/2 transgenic mice took up to 12 times as
long as controls to traverse all the beams ( p , 0.0001).
At 8–9 weeks of age, R6/2 transgenic mice also made signifi-
cantly more footslips than control mice on all but the widest
square and round beams, the frequency of which increased with
age and as the beams became narrower. One obvious difference
between R6/2 transgenic and wild-type control mice was the
manner in which the R6/2 transgenic mice traversed the beams.
At the onset of testing, R6/2 transgenic and wild-type control
mice adopted a stable upright posture, but by 10–11 weeks of age
most R6/2 transgenic mice displayed ventral recumbence: their
thorax and abdomen were flattened against the upper surface of
Figure 1. Body weights of wild-type and R6/2 transgenic mice. Symbols
indicate the means 6 SEM body weight (gram) of wild-type (n 5 22) and
R6/2 transgenic (n 5 9) mice. The body weight of R6/2 transgenic mice
gradually declines from 12 weeks of age. Asterisks indicate significant
differences between wild-type control R6/2 transgenic mice (**p , 0.01).
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each beam, their hind- and forelimbs were wrapped around the
lateral surface of each beam, and their forelimbs were used to
drag themselves along the beam while their hindlimbs became
redundant. By 13–14 weeks of age, some R6/2 transgenic mice
failed to maintain balance on the beams and fell off. When this
occurred on three consecutive trials the animal was no longer
tested. In subsequent trials, for purposes of analysis, such animals
were given a maximum latency of 60 sec and a footslip score of 50,
which equates to the highest number of footslips before outright
failure.
The significance of these observations was confirmed by
ANOVA, which indicated a significant effect of genotype on both
the latency and the number of footslips made while traversing the
different beams (F1,29 5 528.00 and 1441.06, respectively; both
p , 0.0001) and a significant interaction between genotype 3
age 3 beam (shape and size) for both measures (latency: F16,1392
5 4.75; footslips: F16,1392 5 8.69; both p , 0.0001).
Rotarod
Motor coordination and balance of mice were measured using a
rotarod. All mice used in this study showed learning of the
rotarod test and reached a stable level of performance within 3 d,
as measured by an increase in the mean duration time for mice to
maintain balance on the rotarod (data not shown). Throughout
the study control mice maintained balance on the rotarod for the
maximum latency of 60 sec, on all rotation speeds, with the
exception of 33 and 44 rpm, when they would occasionally fall off
(Fig. 4G,H).
R6/2 transgenic mice 5–6 weeks old had difficulty maintaining
balance on the rotarod at the highest rotation speeds of 33 and 44
rpm ( p , 0.0001) (Fig. 4G,H). Thus these changes in rotarod
rotation speeds identify significant deficits in motor coordination
and balance of R6/2 transgenic mice even before any overt phe-
notype is detectable. There was a progressive decline in perfor-
mance of R6/2 transgenic mice on the rotarod at all 10 speeds
over ensuing weeks, and by 13–14 weeks of age R6/2 transgenic
mice failed to maintain balance on the rotarod at any speed for
.10 sec (Fig. 4A–H).
The significance of the difference between groups was con-
firmed by ANOVA, which revealed a highly significant main effect
of genotype (F1,29 5 1868.70, p , 0.0001), genotype 3 speed
(F10,319 5 18.21, p , 0.0001), and genotype 3 age (F6,174 5
350.54, p , 0.0001), and a significant genotype 3 speed 3 age
interaction (F60,1914 5 3.57, p , 0.0001), reflecting a significant
difference between the performance of R6/2 transgenic and con-
trol mice with an increase in rotarod rotation speed and age.
Footprint test
Gait abnormalities were assessed by analyzing the footprint pat-
tern of mice while they walked along a narrow corridor. Footprint
patterns of wild-type and R6/2 transgenic mice at 13–14 weeks of
age are illustrated in Figure 5. At all ages, control mice walked in
a straight line, with a regular even alternating gait, placing the
hindpaw precisely at the position where the ipsilateral forepaw
had been in the previous step (Fig. 5A). By contrast, with increas-
ing age, R6/2 transgenic mice progressively weaved from side to
side while walking along the runway, adopting unevenly spaced
shorter strides, staggering movements, and a gait that lacked a
normal, uniform, alternating left–right step pattern (Fig. 5B).
The resulting footprint patterns were assessed quantitatively by
four measurements: stride length, hindbase width, frontbase
width, and front footprint /hind footprint overlap. Although R6/2
transgenic and control mice exhibited comparable stride lengths
at 5–6 weeks of age, these gradually deviated with age (geno-
type 3 age: F6,174 5 34.01, p , 0.0001) (Fig. 6A). The stride
length of control mice increased significantly with age. By con-
trast, by 8–9 weeks, R6/2 transgenic mice displayed a significantly
shorter stride length compared with control mice ( p , 0.0001),
and this effect became more pronounced as the mice got older
(Fig. 6A).
The hindbase width of R6/2 transgenic mice did not differ from
that of their wild-type littermates throughout the study (geno-
type: F1,29 5 0.92, p 5 0.345; genotype 3 age: F6,174 5 0.97, p 5
0.442) (Fig. 6B). In contrast, the frontbase width of R6/2 trans-
genic mice was significantly broader and more splayed than that
Figure 2. Swimming performance of wild-type and R6/2 transgenic mice
in the swimming tank. Wild-type (n 5 22) and R6/2 transgenic (n 5 9)
mice were tested in the swimming tank for two trials per day for 3
consecutive days at 5–6 weeks of age, retested at 8–9 weeks of age, and
then weekly thereafter. Separate measurements were made of the latency
(A), the number of hindlimb kicks ( B), and the number of forelimb kicks
(C) to swim 60 cm to a visible escape platform. Vertical bars indicate
means 6 SEM of each measure across all trials at each age. R6/2
transgenic mice display swimming impairments at the earliest age tested,
5–6 weeks, which progressively worsen over subsequent weeks. Asterisks
indicate significant differences between wild-type control and R6/2 trans-
genic mice (*p , 0.05, **p , 0.01).
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shown by controls at 8–9 weeks of age, and this difference
was sustained over the five succeeding weeks (genotype: F1,29
5 23.60, p , 0.0001; genotype 3 age: F6,174 5 2.88, p 5 0.013)
(Fig. 6C).
The distance from left or right front footprint /hind footprint
overlap provides an indication of uniformity of step alternation.
As shown in Figure 6D, R6/2 transgenic mice displayed a similar
uniformity in step alternation at 5–6 weeks of age compared with
controls, but by 8–9 weeks of age the regular left–right step
pattern began showing disruption, and they exhibited a progres-
sively greater distance between front and hind footprint place-
ment (i.e., a reduced overlap) as compared with controls. The
progressive difference between R6/2 transgenic and control mice
with age was highly significant (genotype 3 age: F6,174 5 8.06, p ,
0.0001) (Fig. 6D).
Prepulse inhibition of the acoustic startle response
Acoustic startle is a motor reflex response to an intense loud noise
stimulus. As shown in Figure 7A,F, the acoustic startle response
to 120 and 105 dB, respectively, did not differ between control and
R6/2 transgenic mice over the first 10–11 weeks of age, but did
decline in the R6/2 transgenic mice at the final test at 12.5 weeks
of age (genotype 3 age: F3,87 5 4.88, p , 0.01 and F3,87 54.85,
p , 0.007, respectively). It is noteworthy that the change in
magnitude of acoustic startle responses during the course of the
study appeared to parallel the change in body weight of R6/2
transgenic and control mice (Fig. 1).
The acoustic startle response is reduced when a prepulse stim-
ulus is presented before the main startle stimulus. The level of
PPI, expressed as a percentage reduction of the baseline startle
response, obtained with each of the four different prepulses in
Figure 3. Balance and motor coordination
on the raised beams. Wild-type (n 5 22) and
R6/2 transgenic (n 5 9) mice were trained to
walk across six progressively more difficult
beams of square and round cross-section to
reach an enclosed safety platform. The la-
tency to cross (A–F) and the number of
footslips made (G–L) were recorded on
each trial. All animals were given two trials
on each of the graded square and round
beams, in each case progressing from the
widest to the narrowest, for 3 consecutive
days at 5–6 weeks of age, retested at 8–9
weeks of age, and then weekly thereafter.
Individual symbols represent means 6 SEM
of the two groups on each test and age. R6/2
transgenic mice exhibit a progressive de-
cline in beam-walking ability with age and
beam difficulty. Asterisks indicate significant
differences between wild-type control and
R6/2 transgenic mice (*p , 0.05, **p ,
0.01).
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R6/2 transgenic and littermate control mice at different ages of
testing is shown in Figure 7B–E, G–J. At 5 weeks of age, R6/2
transgenic mice and wild-type littermate control mice displayed
comparable PPI at all prepulse intensities. However, compared
with control mice, a significant reduction of PPI was apparent in
R6/2 transgenic mice by 8–9 weeks of age at prepulse intensity
levels of 2 and 4 dB. By 12–13 weeks of age PPI was significantly
disrupted in R6/2 transgenic mice at all four prepulse intensity
levels.
Repeated-measures ANOVA of PPI to 120 and 105 dB startle
stimuli revealed significant effects of genotype (F1,29 5 23.23 and
35.96, respectively; both p , 0.001) and genotype 3 age (F3,87 5
8.02 and 16.18, respectively; both p , 0.001), confirming that the
transgenic mice exhibited a significant progressively greater PPI
deficit as they aged. However, neither the genotype 3 prepulse
intensity (F3,87 5 0.30, p 5 0.828 and F3,87 5 0.22, p 5 0.925,
respectively) nor the genotype 3 prepulse intensity 3 age (120
dB: F9,348 5 0.82, p 5 0.597; 105 dB: F9,348 5 0.60, p 5 0.794)
approached significance, confirming the observation that the age-
dependent deficit in the transgenic mice was apparent and of
similar magnitude at all prepulse intensities, notwithstanding the
fact that the higher intensity prepulses induced a greater inhibi-
tion than lower intensity prepulses in the transgenic and control
mice alike.
DISCUSSION
Motor symptoms play a prominent role in the early stages of HD
(Harper, 1996), and R6/2 transgenic mice have been reported to
display a number of motor abnormalities reminiscent of those
occurring in HD, including dyskinetic movements, resting
tremor, seizures, and locomotor abnormalities (Mangiarini et al.,
1996; Carter et al., 1998; Dunnett et al., 1998). In this study we
tested motor function in R6/2 mice and showed that on all motor
tests performed they display a marked and progressive deterio-
ration in performance, compared with wild-type littermate con-
trol mice.
Behavioral testing commenced at 5–6 weeks of age. This age
was chosen as the starting point because it was several weeks
before overt symptoms first appear in R6/2 mice. However, even
at 5–6 weeks it was apparent that R6/2 transgenic mice exhibited
difficulties in a number of tasks (namely swimming, traversing the
narrowest square raised beam, and maintaining balance on the
rotarod at the fastest rotating speeds). For example, when R6/2
transgenic mice were placed in the swim tank, their abnormal
posture and inappropriate kicking movements contrasted sharply
with the coordinated, synchronized paddling movements shown
by wild-type mice. Thus from 5–6 weeks the R6/2 transgenic mice
swam more slowly and more inefficiently than wild-type control
mice, although there were no deficits seen in the other tests (gait,
sensorimotor gating, or motor performance on the lesser chal-
lenging wider beams and slower rotarod speeds). Furthermore, in
their home cage at this age the transgenic mice were indistin-
guishable from their wild-type littermates by simple observation.
There is therefore no clear “age of onset” of neurological phe-
notype in R6/2 transgenic mice; the age at which a phenotype is
Figure 4. Balance and motor coordination on the ro-
tarod. Wild-type (n 5 22) and R6/2 transgenic (n 5 9)
mice were subjected to eight different speeds on an
accelerating rotarod (5–44 rpm), receiving two trials per
speed. The means 6 SEM of the duration of balance or
latency to fall (maximum trial length 5 60 sec) for the
two trials at each speed level was recorded. Animals 5–6
weeks old were tested to establish baseline performance,
and animals were retested at 8–9 weeks of age and then
weekly thereafter. R6/2 transgenic mice 5–6 weeks old
exhibit difficulty maintaining balance on the rotarod at
the highest rotation speeds (G, H ) and display a progres-
sive decline in performance on the rotarod with increas-
ing rotation speed and age. Asterisks indicate significant
differences between wild-type control and R6/2 trans-
genic mice (*p , 0.05, **p , 0.01).
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apparent depends on the sensitivity of the test and the difficulty of
the particular task used to characterize it. Even if a mouse
appears “normal” on inspection, a more sensitive test may reveal
significant deficits in fine motor control and motor coordination.
By 8 weeks of age, signs of neurological abnormality in R6/2
mice were occasionally observed in the home cage, in particular
stereotypical hindlimb grooming movements. The stereotypical
grooming increased in frequency between 8 and 12 weeks, and at
the same time, other deficits in motor activity became apparent.
In particular, balance and coordination become increasingly im-
paired, and dyskinesia and resting tremor ensued. The frequency
and severity of these abnormalities worsened gradually, until by
11 weeks of age the mice groomed frequently, there were clear
signs of a constant resting tremor, and occasional epileptic sei-
zures were evident. Concurrent with the onset of severe motor
deficits, and consistent with the findings of Davies et al. (1997),
R6/2 mice showed a progressive loss of body weight, compared
with littermate controls. In our study this was not until 12 weeks
of age, nearly 2 months after motor deficits were first observed.
Therefore the motor deficits reported here cannot be attributed
to loss of body weight. This suggests that the onset of motor
symptoms is a consequence of the transgene rather than changes
in body weight. It is interesting that although they developed the
overt neurological phenotype at a similar time, mice in our colony
in Cambridge began to lose weight nearly 4 weeks later than
reported previously (Davies et al., 1997). Because their genetic
background is the same as the original colony, we attribute the
differences between the two colonies to changes in husbandry of
our colony resulting in improved access to food and water.
Between 8 and 14 weeks of age, the performance of R6/2
transgenic mice in the swimming tank test worsened progres-
sively. Performance on the beam and rotarod also deteriorated
over this time, with the mice taking significantly longer to traverse
all six beam types, exhibiting a greater number of footslips, and
Figure 5. Representative walking footprint patterns of 13- to 14-week-
old wild-type (A) and R6/2 transgenic (B) mice. Qualitatively, the gen-
erated patterns clearly differ showing that R6/2 transgenic mice display
irregularly spaced shorter strides and an uneven left–right step pattern as
compared with the evenly spaced and accurately positioned footprints of
the wild-type control mice.
Figure 6. Quantitative analysis of the walking footprint patterns pro-
duced by wild-type and R6/2 transgenic mice, based on measurements of
stride length ( A), hindbase width ( B), frontbase width ( C), and distance
between front and hind footprint placement or overlap (D). At 5–6 weeks
of age the footprint patterns of R6/2 transgenic mice are indistinguishable
from those produced by wild-type control mice, but by 8–9 weeks of age,
R6/2 transgenic mice exhibit a significantly shorter stride length, a broader
frontbase width, and a greater distance between front footprint /hind
footprint overlap, as compared with wild-type control mice. Symbols
indicate means 6 SEM by mice of each group at each age on each
measure. Asterisks indicate significant differences in the performance of
wild-type control and R6/2 transgenic mice (*p , 0.05, **p , 0.01).
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failing to maintain balance on the rotarod at all rotation speeds.
Deficiencies in gait also became apparent from 8 weeks of age. By
12 weeks these deficits were pronounced; instead of walking in a
straight line with evenly spaced and accurately positioned foot-
prints, R6/2 transgenic mice often weaved from side to side,
adopting staggering movements, irregularly spaced shorter
strides, and a gait that lacked a normal, uniform, alternating
left–right step pattern. Notably, these abnormalities were similar
to gait disturbances described in patients with HD (Koller and
Trimble, 1985; Harper, 1996) and also in 3-NP treated rats
(Guyot et al., 1997). This latter observation is particularly inter-
esting, because we have observed that the manner in which the
R6/2 mice and 3-NP-treated rats traversed the beams is also very
similar (R. J. Carter and A. J. Morton, unpublished observa-
tions). Because 3-NP treatment is a widely accepted model of the
striatal pathology in HD, and the behavioral changes shown by
3-NP-treated rats have been attributed to selective striatal dam-
age (Guyot et al., 1997), the striking similarities in the motor
deficits of 3-NP-treated rats and R6/2 transgenic mice suggest
that despite the absence of striatal neuronal loss, the motor
deficits seen in R6/2 transgenic mice arise from striatal
dysfunction.
R6/2 transgenic mice exhibited normal acoustic startle re-
sponses until relatively late in the study when 12- to 13-week-old
R6/2 transgenic mice revealed a decline on both startle measures.
In contrast, the degree to which a prepulse inhibits the acoustic
startle reflex was significantly reduced in R6/2 transgenic mice at
8 weeks of age (at the most sensitive, i.e., lowest, prepulse inten-
sities). The impairment in PPI in R6/2 mice increased with age,
consistent with the progressive impairment in PPI seen in pa-
tients with HD (Swerdlow et al., 1995). PPI of the acoustic startle
response has also been reported in rats after quinolinic acid
Figure 7. Prepulse inhibition of the acoustic star-
tle response in wild-type (n 5 22) and R6/2 trans-
genic (n 5 9) mice. Symbols indicate mean 6 SEM
of the response of the two groups at different ages
to white noise stimuli of 120 dB (A–E) and 105 dB
(F–J ) with either the baseline startle response re-
corded to the primary acoustic startle stimulus
alone (A, F, respectively) or with 100 msec prepulse
warning stimuli of rising intensities (2, 4, 8, and 16
in B–E and G–J, respectively). R6/2 transgenic
mice exhibit impaired PPI by 8–9 weeks of age, and
this impairment progressively declines with age.
Asterisks indicate significant differences in perfor-
mance between the two genotypes (*p , 0.05,
**p , 0.01).
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lesions of the striatum or systemic 3-NP treatment (Kodsi and
Swerdlow, 1995, 1997). Because the response of R6/2 transgenic
mice to the basic acoustic startle only differed from that of control
mice at a relatively late age (and the analysis of PPI is corrected
for baseline level of startle), the loss of PPI in R6/2 transgenic
mice is unlikely to be caused simply by a generalized muscular
weakness but suggests that in R6/2 mice (as in humans) abnor-
malities in PPI are derived from sensorimotor deficits in the CNS.
There is at present no unequivocal neuropathological substrate
for the progressive deterioration in the motor performance of
R6/2 transgenic mice. Previous work has shown that although by
12 weeks of age the brains of R6/2 transgenic mice weigh ;20%
less than those of wild-type control mice, there is no selective
striatal cell loss (Mangiarini et al., 1996; Davies et al., 1997).
Recent studies, however, show that R6/2 transgenic mice have
neuropathological changes; in particular they develop neuronal
intranuclear inclusions (NIIs) (Davies et al., 1997) and display a
decreased expression of dopamine (D1, D2 ) and mGluR1 recep-
tor mRNA in the striatum (Cha et al., 1998), from as early as 4–5
weeks of age. Similar NIIs have been found in postmortem brains
of patients with HD (Di Figlia et al., 1997), and postmortem
changes in dopamine receptors in HD have been well docu-
mented (Harper, 1996). Thus, it seems possible that the motor
abnormalities we observed in R6/2 transgenic mice are attribut-
able to dysfunction of the striatum, despite the lack of neuronal
cell death in the striatum.
It is not yet known why neuronal loss is not seen in brains of
R6/2 mice. The most likely explanation is that the early and
sudden death of these mice occurs before neuronal loss is evident.
However, although at first sight the lack of striatal neurodegen-
eration is a weakness of the model, striatal dysfunction without
cell death is also seen in HD. The onset of motor symptoms in
HD patients does not correlate well with neuropathological grad-
ing, although this issue is complicated by the enormous variation
in the presentation of motor symptoms in HD. Although few
systematic studies relating clinical symptoms and neuropathology
in early stage HD have been performed, Meyers et al. (1988)
described five patients who died with clinical features of the
disease, including chorea and other involuntary movements, yet
had no discernible neuropathological abnormalities (Grade 0
pathology). Notably, one of these patients had shown choreiform
motor abnormalities for 4 years before his death, yet still showed
no neuronal loss. These findings are similar to our findings in the
mice and support the suggestion that R6/2 transgenic mice may
not only provide a relevant genetic model of HD, but may also
demonstrate a progressive neurological phenotype that is directly
comparable to that seen in early HD.
Our study describes detailed motor and sensorimotor changes
in R6/2 transgenic mice that progressively worsen with age and
with test difficulty. The quantifiable progression of these motor
deficits makes this R6/2 transgenic mouse model particularly
suitable for assessing the effectiveness of potential therapeutic
agents and repair strategies for treating the motor symptoms of
HD. Moreover, this model of HD offers a unique system in which
the testing of experimental treatments for HD can be performed
even before an overt phenotype has developed.
Note
Since this work was submitted, we have become aware that
diabetes is present in R6/2 transgenic mice. We have tested the
mice in our colony and confirm that we have diabetic mice;
indeed, diabetes is common in R6/2 mice .14 weeks of age.
However, we have found neither elevated blood glucose nor
urinary glucose to be present under a normal feeding regime in
mice ,9 weeks of age. Furthermore, of the mice used in this
study, at 13 weeks only two of eight transgenic mice tested had
elevated blood glucose levels (14 mmol/ l, 27.8 mmol/ l) and glu-
cose in the urine (14 mmol/ l, 27.8 mmol/ l). The remaining six
mice had normal plasma glucose levels (4–8 mmol/ l) and no
glucose in their urine. Therefore, during the critical testing pe-
riod (5–10 weeks of age) in our study, we believe that any
deleterious effects that might be associated with diabetes are
unlikely to have contributed to the behavioral phenotype we
observed in R6/2 mice.
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